Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

AstraZeneca
McKinsey
Express Scripts
Harvard Business School
Merck
Mallinckrodt

Last Updated: October 17, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR OLAPARIB

See Plans and Pricing

« Back to Dashboard

Clinical Trials for Olaparib

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00494234 Study to Assess the Efficacy and Safety of a PARP Inhibitor for the Treatment of BRCA-positive Advanced Breast Cancer Active, not recruiting KuDOS Pharmaceuticals Limited Phase 2 2007-06-01 The purpose of the study is to see if the drug KU 0059436 (olaparib) is effective and well tolerated in treating patients with measurable BRCA1- or BRCA2-positive advanced breast cancer and for whom no curative therapeutic option exists.
NCT00494234 Study to Assess the Efficacy and Safety of a PARP Inhibitor for the Treatment of BRCA-positive Advanced Breast Cancer Active, not recruiting AstraZeneca Phase 2 2007-06-01 The purpose of the study is to see if the drug KU 0059436 (olaparib) is effective and well tolerated in treating patients with measurable BRCA1- or BRCA2-positive advanced breast cancer and for whom no curative therapeutic option exists.
NCT00494442 Study to Assess the Efficacy and Safety of a PARP Inhibitor for the Treatment of BRCA-positive Advanced Ovarian Cancer Active, not recruiting KuDOS Pharmaceuticals Limited Phase 2 2007-06-01 The purpose of the study is to see if the drug KU 0059436 is effective and well tolerated in treating patients with measurable BRCA1- or BRCA2-positive advanced ovarian cancer and for whom no curative therapeutic option exists.
NCT00494442 Study to Assess the Efficacy and Safety of a PARP Inhibitor for the Treatment of BRCA-positive Advanced Ovarian Cancer Active, not recruiting AstraZeneca Phase 2 2007-06-01 The purpose of the study is to see if the drug KU 0059436 is effective and well tolerated in treating patients with measurable BRCA1- or BRCA2-positive advanced ovarian cancer and for whom no curative therapeutic option exists.
NCT00515866 Study to Assess the Safety & Tolerability of a PARP Inhibitor in Combination With Gemcitabine in Pancreatic Cancer Completed AstraZeneca Phase 1 2007-08-01 The purpose of this study is to identify a safe and tolerable dose of the drug KU-0059436 that can be given in combination with gemcitabine chemotherapy for the treatment of pancreatic cancer.
NCT00516373 A Study to Assess the Safety and Pharmacokinetics of an Inhibitor of Poly ADP-Ribose Polymerase-1 (PARP) Active, not recruiting AstraZeneca Phase 1 2005-07-01 To determine the safety, tolerability, dose-limiting toxicity (DLT), pharmacokinetic-pharmacodynamic profile, and maximum tolerated dose (MTD) of KU-0059436 when administered orally to patients with advanced solid tumours. To further evaluate the safety and efficacy of KU-0059436 in an expanded cohort of BCRA-enriched population, primarily ovarian cancer patients.
NCT00516438 Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Topotecan Completed KuDOS Pharmaceuticals Limited Phase 1 2007-07-01 The purpose of this study is to identify a safe and tolerable dose of the drug KU-0059436 that can be given in combination with topotecan chemotherapy in patients with advanced solid tumours
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Olaparib

Condition Name

Condition Name for Olaparib
Intervention Trials
Ovarian Cancer 20
Breast Cancer 19
Recurrent Primary Peritoneal Carcinoma 9
Recurrent Fallopian Tube Carcinoma 8
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Olaparib
Intervention Trials
Ovarian Neoplasms 46
Breast Neoplasms 38
Carcinoma 29
Neoplasms 25
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Olaparib

Trials by Country

Trials by Country for Olaparib
Location Trials
United States 576
Canada 67
United Kingdom 61
Spain 47
Italy 36
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Olaparib
Location Trials
New York 34
California 33
Massachusetts 31
Pennsylvania 28
Texas 27
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Olaparib

Clinical Trial Phase

Clinical Trial Phase for Olaparib
Clinical Trial Phase Trials
Phase 4 1
Phase 3 22
Phase 2/Phase 3 3
[disabled in preview] 191
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Olaparib
Clinical Trial Phase Trials
Not yet recruiting 88
Recruiting 86
Active, not recruiting 30
[disabled in preview] 17
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Olaparib

Sponsor Name

Sponsor Name for Olaparib
Sponsor Trials
AstraZeneca 125
National Cancer Institute (NCI) 35
Merck Sharp & Dohme Corp. 9
[disabled in preview] 29
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Olaparib
Sponsor Trials
Other 195
Industry 188
NIH 35
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Dow
Boehringer Ingelheim
Colorcon
Medtronic
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.